iDose TR
ApprovedSmall molecule
iDose TR is one of 61 small molecule programs targeting Glaucoma. It is currently in Approved.
2
Indications
2
Total Trials
2
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
219 competitors in Cataract
#DrugCompanyPhaseTrials
1Isopto Carpine
AAdvanz Pharma
Phase 3
Clobetasol Propionate
BayerPhase 3
Intranasal Dexmedetomidine
BBaudax Bio
Phase 3
Mapracorat
BayerPhase 3
iDose TR
GGlaukos Corporation
Approved
Ripasudil
KKowa Research Institute, Inc.
Phase 3
XG-102
XXigen SA
Phase 3
Midalozam
Idorsia Pharmaceuticals Ltd.Phase 3
Zolymbus
AbbViePreclinical
Neurontin
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for iDose TR. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- GGlaukos Corporation